Therapeutic effects of mesenchymal stem cells on cutaneous leishmaniasis lesions caused by Leishmania major
| Autor: | Alireza Nourian, Mohammad Hossein Feiz Haddad, Mohammad Amin Behmanesh, Selman A. Ali, Mohamadreza Baghaban Eslaminejad, Hossein Rezvan, Sahar Hamoon Navard |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Microbiology (medical)
Immunology Leishmaniasis Cutaneous Spleen Microbiology Cell therapy Mice Immune system Antigen Cutaneous leishmaniasis medicine Immunology and Allergy Animals Leishmania major Mice Inbred BALB C Meglumine Antimoniate biology business.industry Mesenchymal stem cell Leishmania biology.organism_classification medicine.disease QR1-502 medicine.anatomical_structure Mesenchymal stem cells business BALB/c |
| Zdroj: | Journal of Global Antimicrobial Resistance, Vol 23, Iss, Pp 243-250 (2020) |
| ISSN: | 2213-7165 |
| Popis: | Objectives Leishmania major (L. major) is a cutaneous leishmaniasis causative agent. Current chemotherapeutic methods are not totally effective in treatment of this disease. The immunomodulation and tissue repairing capability of mesenchymal stem cells (MSCs), ease of isolation, detection and in vitro culture, have encouraged biologists to use MSCs for cell therapy in different infections such as cutaneous leishmaniasis. Methods BALB/c mice (6–8 weeks old) were infected with L. major then divided into four groups and treated with MSCs, Glucantime, Glucantime + MSCs, or PBS. Regression of lesions, potency of macrophages for phagocytosis, proliferation of immune cells against Leishmania soluble antigen, reduction of spleen parasite burden and healing of the lesions were evaluated on days 10, 20 and 30 of treatment. Results The results indicated that the mice intralesionally injected with MSCs showed significant regression in the lesions produced by L. major by day 30. Proliferation of splenocytes stimulated with SLA (soluble leishmania antigen) in vitro in MSC-treated mice on day 20 was significantly higher than in the other groups. The potency of phagocytosis in macrophages of mice treated with MSCs was significantly higher by day 30 and healing of the lesions in this group of mice showed more progress on histopathological examinations. Spleen parasite burden showed significant reduction in the mice treated with Glucantime + MSCs by day 30. Conclusions The results showed that including MSCs in treatment of cutaneous leishmaniasis caused by L. major is a promising approach. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect